NFKB1 and breast carcinoma: On the basis of the observation that GD2 expression in breast cancer cells is associated with stem cell-like behavior and with activated NF-κB signalling [48], a small-molecule inhibitor of NF-κB has been investigated as a therapeutic agent in preclinical studies.